Friday, February 7, 2025
HomeBusinessAurobindo Pharma shares decline after U.S. FDA inspection report to subsidiary’s API...

Aurobindo Pharma shares decline after U.S. FDA inspection report to subsidiary’s API plant 


Generic drugmaker Aurobindo Pharma’s shares ended more than 3% lower on Tuesday in the backdrop of U.S. Food and Drug Administration issuing an establishment inspection report with a voluntary action indicated (VAI) classification to subsidiary Apitoria Pharma’s active pharmaceutical ingredient plant near Hyderabad.

The U.S. FDA inspection of Unit-2, the API manufacturing facility of Apitoria Pharma in Jinnaram Mandal, Sanga Reddy district, conducted from September 23-27, had concluded with the regulator issuing 10 observations.

The unit has since received an EIR classifying the facility as VAI, the parent company said in a filing. Aurobindo Pharma shares closed 3.19% lower at ₹1,137.75 each on the BSE.



Source link

RELATED ARTICLES

Most Popular

Recent Comments